CTLA4 and melanoma: In 2016, Heppt et al. performed a retrospective analysis of 33 highly pretreated stage III–IV melanoma patients who received systemic immunotherapy, with either anti-CTLA-4 (n = 28) or anti-PD1 (n = 5) agents, combined with ECT.